



CLINICAL TRIAL PROTOCOL

A randomized, placebo-controlled trial of patient education for acute low back pain (PREVENT Trial): statistical analysis plan

Adrian C. Traeger^{a,b,*}, Ian W. Skinner^{a,b}, Markus Hübscher^{a,b}, Hopin Lee^{a,b}, G. Lorimer Moseley^{b,c}, Michael K. Nicholas^d, Nicholas Henschke^e, Kathryn M. Refshauge^f, Fiona M. Blyth^g, Chris J. Main^h, Julia M. Hushⁱ, Garry Pearce^j, Serigne Lo^k, James H. McAuley^{a,b}



^a Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia

^b Neuroscience Research Australia, Sydney, New South Wales, Australia

^c Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia

^d Pain Management Research Institute, University of Sydney at Royal North Shore Hospital, Sydney, New South Wales, Australia

^e Institute of Public Health, University of Heidelberg, Heidelberg, Germany

^f Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia

^g Centre for Education and Research on Ageing, University of Sydney, Sydney, New South Wales, Australia

^h Arthritis Care UK National Primary Care Centre, Keele University, North Staffordshire, UK

ⁱ Department of Health Professions, Macquarie University, Sydney, New South Wales, Australia

^j Department of Rehabilitation Medicine, Greenwich Hospital, Sydney, New South Wales, Australia

^k Melanoma Institute Australia, Sydney, New South Wales, Australia

Received 10 January 2017; accepted 23 January 2017

Available online 14 April 2017

KEYWORDS

Low back pain;
Patient education;
Preventive medicine;
Primary care

Abstract

Background: Statistical analysis plans increase the transparency of decisions made in the analysis of clinical trial results. The purpose of this paper is to detail the planned analyses for the PREVENT trial, a randomized, placebo-controlled trial of patient education for acute low back pain.

Results: We report the pre-specified principles, methods, and procedures to be adhered to in the main analysis of the PREVENT trial data. The primary outcome analysis will be based on Mixed Models for Repeated Measures (MMRM), which can test treatment effects at specific time points, and the assumptions of this analysis are outlined. We also outline the treatment of secondary outcomes and planned sensitivity analyses. We provide decisions regarding the treatment of missing data, handling of descriptive and process measure data, and blinded review procedures.

* Corresponding author at: McAuley Group, Neuroscience Research Australia, Australia.

E-mail: a.traeger@neura.edu.au (A.C. Traeger).

Conclusions: Making public the pre-specified statistical analysis plan for the PREVENT trial minimizes the potential for bias in the analysis of trial data, and in the interpretation and reporting of trial results.

Trial registration: ACTRN12612001180808 (<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612001180808>)

© 2017 Associação Brasileira de Pesquisa e Pós-Graduação em Fisioterapia. Published by Elsevier Editora Ltda. All rights reserved.

Background

Low back pain is the most burdensome health problem worldwide¹ and one that is seen commonly in primary care.² People with low back pain who seek healthcare place high-value on receiving information and education about the problem.³ Indeed, all clinical guidelines endorse patient education in primary care.⁴ There is good evidence that primary care-based patient education, both face-to-face and written format, reduces emotional distress and subsequent healthcare use for acute low back pain.⁵

Despite widespread recommendations, few practitioners provide patient education in practice.⁶ One reason for lack of uptake could be the belief that conservative treatments such as patient education do not primarily change pain.⁷ For patients with chronic low back pain there is good evidence that this belief is mistaken.⁸ For patients with acute low back pain, however, evidence that patient education alone can reduce pain is lacking.⁹ Furthermore, no study has subjected face-to-face patient education to the gold standard placebo controlled trial, to control for the effects of spending time with a professional.

The PREVENT Trial¹⁰ was the first randomized, placebo-controlled trial of face-to-face patient education for acute low back pain. The purpose of this Statistical Analysis Plan is to outline planned statistical analysis methods for the primary and secondary outcomes of the trial.

Trial overview

The trial is a two-arm placebo-controlled trial. Patients were randomized to receive two, 1-h sessions of *Patient Education* based on Explain Pain¹¹ or two, 1-h sessions of *Sham Education* based on a reflective, non-directive approach,¹² in addition to guideline-based care for acute low back pain. The PREVENT Trial was funded by the National Health and Medical Research Council of Australia (NHMRC APP1047827). It was prospectively registered (ACTRN=12612001180808) and the study protocol has been published elsewhere.¹⁰ Patients were followed up at 3, 6, and 12 months post-randomization.

Trial objectives

Primary objective

Determine whether *Patient Education* in addition to clinical guideline-based care for acute low back pain reduces the

intensity of low back pain at 3 months compared to *Sham Education* in addition to clinical guideline-based care.

Secondary objectives

Determine whether any effect of *Patient Education* on the intensity of low back pain at 3 months compared to *Sham Education* can be maintained at 6 and 12 months.

Determine whether *Patient Education* increases the proportion of patients who recover from low back pain (i.e. who do not develop chronic low back pain) by 3 months compared to *Sham Education*.

Determine whether *Patient Education* can reduce disability, depression, pain attitudes, or healthcare use at 3, 6 and 12 months, compared to *Sham Education*.

Statistical analysis

General principles

Two researchers blind to group allocation will perform the analysis independently. That is, the researcher will know which participants share a group, but not which group that is. All results will be cross-checked for errors. In cases where participants did not receive the treatment as allocated, treatment evaluation will be based on the principle of intention-to-treat. In other words, the analysis will only include observed responses from participants in the trial arm they were allocated to, regardless of whether they complied with the treatment and even if the last observed response was baseline. We will calculate and interpret between group differences and 95% confidence intervals for all outcomes. Statistical tests will be two-tailed with alpha set at $p = <0.05$.

Process measures

Adherence

We recorded attendance for all participants at both trial sessions using a study calendar. We will use these data to assess whether the proportion of participants who successfully completed both trial sessions was different between trial arms. If >5% of participants do not complete both trial sessions, we will compute a "Complier Average Causal Effect".¹³




Figure 1 CONSORT 2010 flow diagram for planned reporting of the PREVENT Trial.

Treatment fidelity

We assessed treatment fidelity by audio recording the trial sessions. Two researchers, experts in *Patient Education* (LM) and *Sham Education* (MN) who are blinded to group allocation, will evaluate a random 10% sample of the trial session recordings to determine whether the participant was receiving *Patient Education* or *Sham Education*. Kappa will be used to determine agreement.

Credibility

We assessed credibility using the Credibility and Expectancy Questionnaire¹⁴ immediately after the trial physical therapist provided the treatment rationale. We will compare the between group mean scores of the Credibility and Expectancy Questionnaire using *t* test to evaluate whether treatment credibility was different in each trial arm.

Blind review of data integrity and handling

All data were collected using online forms. Because the online data collection system required only minimal handling, data will be checked but not double entered as we originally planned and as stated in our protocol.¹⁰ To ensure

data integrity, a blind assessor will check each variable for out of range or implausible values. Once all data have been checked, we will import the dataset in panel format, into Stata V13.¹⁵

Participant recruitment and retention

A flow chart describing the numbers of individuals at each stage of the trial from eligibility to final assessment will be reported, according to the CONSORT statements¹⁶ (see Fig. 1).

Baseline description

We will examine the distribution of all baseline variables stratified by treatment group. Continuous variables will be summarized using the following statistics: number (non-missing sample size), mean and standard deviation for approximately normally distributed variables; median, minimum, maximum and interquartile range for non-normally distributed variables. Normality will be evaluated using frequency histogram and skewness statistics. The number of missing observations will also be reported. Categorical variables will be summarized by percentages along with their frequencies (numerator) and the number of patients

for whom data are available (denominator). Difference between arms will not be tested statistically, but any important imbalance, based on the judgment of the research team, will be mentioned and will be marked with an asterisk (*).

Primary analysis

We calculated that a sample size of 202 participants would provide an 80% power of detecting a mean difference between trial arms of one-point on a 10-point pain intensity scale assuming a standard deviation of 2.3, an α of .05, and allowing 15% loss to follow-up.¹⁰ To determine the effect of *Patient Education* on pain intensity we will use longitudinal mixed models.¹⁷ In longitudinal studies such as randomized trials, mixed models can produce unbiased estimates of treatment effects. A mixed model contains both fixed and random effects. In this analysis, the intervention will be modeled as a fixed effect and, to account for the dependence of repeated measures, the intercepts will be modeled as random effect (Eq. (1)). We will use an unstructured correlation matrix to specify the model. Our expectation is that the outcome of pain intensity will be normally distributed. Time will be treated as a dummy-coded categorical variable and we will examine group \times time interactions to determine treatment effects. Conclusions about the effectiveness of *Patient Education* will be based on the group \times time interaction effect and its 95% confidence interval at 3 months.

Eq. (1) – Mixed Model for Repeated Measures (MMRM) regression equation for the primary analysis (based on Ashbeck and Bell)¹⁸:

$$\begin{aligned} Y_{ij} = & \beta_1 t1 + \beta_2 t2 + \beta_3 t3 + \beta_4 t4 + \beta_5 treat_i \times t1 \\ & + \beta_6 treat_i \times t2 + \beta_7 treat_i \times t3 \\ & + \beta_8 treat_i \times t4 + \beta i + e_{ij} \end{aligned} \quad (1)$$

where Y_{ij} is the outcome for the i th participant at the j th time, $i=1,\dots,n=202$, $j=1, 2, 3, 4$, $t1$ is indicator variable for time 1 (baseline), $t2$ for time 2 (3 months), $t3$ for time 3 (6 months), $t4$ for time 4 (12 months), $treat_i=0$ (control), $treat_i=1$ (treatment). The effects of the treatment and the treatment-time interaction are modeled as fixed effects.

$\beta_i = \sim N(0, \sigma_b^2)$ between-person effects, with σ_b^2 between-person variance. The between-person effects are modeled as random effects. $e_{ij} = \sim N(0, \sigma_e^2)$ within-person effects, with σ_e^2 within-person variance.

Assumptions of the Mixed Model for Repeated Measures (MMRM) analysis

The mixed model analysis requires assumptions about the data. These include independence of observations, normality and heteroscedasticity. Missing data are assumed to be Missing at Random. Missing at Random describes the probability of a missing observation being independent of prior observations but conditional on other observed values. MMRM analyses also assume a correlation structure between the repeated measurements. The correlations can be fixed (structured model), decaying (autoregressive model) or unconstrained (unstructured model). We have

assumed unconstrained correlations between the repeated assessments.

Secondary analysis

Persistence of effects on pain and disability

To evaluate the effects of *Patient Education* on pain intensity at 6 and 12 months, we will examine the relevant group \times time interactions from the longitudinal mixed model used for the primary analysis. We will build a separate model to examine intervention effects on disability at 3, 6 and 12 months. We will specify the disability model in the same way as in the primary analysis (Eq. (1)), exchanging the Y outcome variable to disability measured on a continuous scale (Roland Morris Disability Questionnaire).¹⁹

Development of chronic low back pain

To assess the number of participants who transition from acute low back pain to chronic low back pain we will categorize participants according to our definition of chronic low back pain: $\geq 2/10$ pain intensity and no periods of recovery at 3 month follow-up.¹⁰ To evaluate the effects of *Patient Education* on the development of chronic low back pain, we will estimate the ratio of the odds of having chronic low back pain using a Generalized Mixed Effects Model with a logit link and a random intercept. The model will provide odds ratio between the two arms of experiencing a transition from acute to chronic low back pain.

Short- and long-term effects on pain, disability, depression, pain attitudes and healthcare use

We will undertake exploratory analyses on all secondary outcomes. To test intervention effects on continuous secondary outcomes (disability, depression, pain, global change, pain attitudes and healthcare visits) we will examine group \times time interactions from the longitudinal mixed models at each follow-up time point.

Four secondary outcomes were categorical variables: healthcare use (passive modalities, e.g. medication, manual therapy vs active modalities, e.g. exercise, rehabilitation); choice of practitioner; recurrence; further investigations required. For the outcomes with two categories we will use logistic regression models to determine between group differences. For the outcome with four categories (choice of practitioner), we will use a multinomial logistic regression.

Sensitivity analysis

Out-of-trial therapy

We will evaluate the effect of out-of-trial therapy (number of healthcare visits) as a post-randomization confounder. The purpose of this sensitivity analysis is to assess the influence of *Sham Education*, which may have unintentionally led participants to seek out-of-trial therapy. We will conduct a mediation analysis to estimate the natural direct effect²⁰ of *Patient Education* on pain intensity at 3 months that eliminates the indirect effect of *Sham Education* on pain intensity through out-of-trial therapy.

Reporting data

Continuous outcomes (e.g. low back pain intensity scale) will be summarized by number of data available, mean and standard deviation at each data collection point (Baseline, 3, 6 and 12 months). We will display the treatment effect, estimated as the mean pain intensity scale difference at each time point, along with the corresponding 95% confidence interval and the level of significance. Categorical variables will appear as frequencies and percentages at each time point. We will report overall odds ratios (95% confidence interval) and the level of significance.

Contributions

The original study was conceived and designed by ACT, GLM, MH, HL, IWS, NH, JMH, KMR, FMB, CJM, GP, and JHM. The analysis plan was developed by JHM, ACT, MH, HL, SL, and IWS. ACT prepared the first draft of the manuscript. Successive drafts were contributed by ACT, GLM, MH, HL, IWS, NH, JMH, KMR, FMB, CJM, SL and JHM. The final version of the manuscript was approved by all authors.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;386(9995):743–800.
2. Deyo RA, Weinstein JN. Low back pain. *N Engl J Med*. 2001;344(5):363–370.
3. Jackson JL, Kroenke K. The effect of unmet expectations among adults presenting with physical symptoms. *Ann Intern Med*. 2001;134(9 Pt 2):889–897.
4. Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. *Eur Spine J*. 2010;19(12):2075–2094.
5. Traeger AC, Hubscher M, Henschke N, Moseley GL, Lee H, McAuley JH. Effect of primary care-based education on reassurance in patients with acute low back pain: systematic review and meta-analysis. *JAMA Intern Med*. 2015;175(5):733–743.
6. Williams CM, Maher CG, Hancock MJ, et al. Low back pain and best practice care: a survey of general practice physicians. *Arch Intern Med*. 2010;170(3):271–277.
7. Ballantyne JC, Sullivan MD. Intensity of chronic pain — the wrong metric? *N Engl J Med*. 2015;373(22):2098–2099.
8. Saragiotto BT, Maher CG, Traeger AC, Li Q, McAuley JH. Dispelling the myth that chronic pain is unresponsive to treatment. *Br J Sports Med*. 2016, <http://dx.doi.org/10.1136/bjsports-2016-096821>.
9. Engers A, Jellema P, Wensing M, van der Windt DA, Grol R, van Tulder MW. Individual patient education for low back pain. *Cochrane Database Syst Rev*. 2008;1. CD004057.
10. Traeger AC, Moseley GL, Hubscher M, et al. Pain education to prevent chronic low back pain: a study protocol for a randomised controlled trial. *BMJ Open*. 2014;4(6):e005505.
11. Butler DS, Moseley GL. Explain Pain. Noigroup Publications. 2003.
12. Pengel LH, Refshauge KM, Maher CG, Nicholas MK, Herbert RD, McNair P. Physiotherapist-directed exercise, advice, or both for subacute low back pain: a randomized trial. *Ann Intern Med*. 2007;146(11):787–796.
13. Yau LH, Little RJ. Inference for the complier-average causal effect from longitudinal data subject to noncompliance and missing data, with application to a job training assessment for the unemployed. *J Am Stat Assoc*. 2001;96(456):1232–1244.
14. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry*. 2000;31(2):73–86.
15. StataCorp. *Stata Statistical Software: Release 13*. College Station, TX: StataCorp LP; 2013.
16. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.
17. Twisk JW. *Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide*. Cambridge: University Press; 2013.
18. Ashbeck EL, Bell ML. Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data. *BMC Med Res Methodol*. 2016;16:43.
19. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. *Spine (Phila PA 1976)*. 1983;8(2):141–144.
20. VanderWeele TJ. A three-way decomposition of a total effect into direct, indirect, and interactive effects. *Epidemiology*. 2013;24(2):224–232.